In particular, in melanoma patients, after demonstrating the correlation between [99mTc]Tc-HYNIC-IL2 and CD25 + cells detected at immunohistochemistry within TME [19], this strategy was also successfully used to predict response of each single lesion to Ipilimumab therapy in metastatic patients [24]. Here, IL2RA is linked to melanoma.